Track Record of Identifying Rare Wealth CreatorsTrack Record of Identifying Rare Wealth Creators

Blogs

April 23, 2026
Bar Chart Showing Debt to equity by Fiscal Year Fy20fy25 Values Fall from 28 to 11 Fy25 Bar is Green

Debt-to-Equity Ratio: The Single Most Important Leverage Metric Every Indian Value Investor Must Master

The Debt-to-Equity Ratio is the single most important leverage filter every Indian value investor must master. Titan Biotech FY25's ₹3 Cr borrowings against a strong net worth produces a sub-0.05x D/E — a textbook illustration of a fortress balance sheet.
April 23, 2026
Horizontal Bar Chart of Yearly Multibagger Shares fy20fy25 Fy20 28 Fy21 26 Fy22 22 Fy23 18 Fy24 14 Fy25 11 fy25 Bar in Green

Invert, Always Invert: Charlie Munger’s Cornerstone Mental Model for Avoiding Small-Cap Disasters in Indian Value Investing

Charlie Munger's favourite mental model — invert the question. Instead of 'how do I find the next multibagger?', ask 'how do I guarantee small-cap losses?' A disciplined Indian inversion checklist, illustrated by Titan Biotech's FY25 audited numbers.
April 22, 2026
Infographic Titled Switching Costs Horizontal Bar Chart of Yearly Costs Fy20fy25 Values 28 26 22 18 14 11 with Fy25 Bar in Green

Switching Costs: The Invisible Lock-In That Protects Great Businesses for Decades

Switching Costs becomes more useful when investors translate it into audited numbers, cleaner disclosure, and better minority-shareholder readability.
April 22, 2026
Hero Header with Title the Endowment Effect and Subtitle Followed by a Two by two Color Grid Labeled Lucky Disciplined Investor Confused Bias trapped on a Dark Blue Background

The Endowment Effect: Why Indian Investors Overvalue What They Already Own

Richard Thaler (1980) and Kahneman-Knetsch-Thaler (1990) explain why Indian retail investors cling to inherited, IPO-allotted, and COVID-era holdings. SEBI, NSE and IIM Bangalore data + a six-step de-biasing checklist from Graham/Buffett/Munger/Klarman, with Titan Biotech (BSE:524717) FY25 audited numbers as the illustrative anti-endowment corporate case study.
+91-7380122211